Cardiovascular disease in systemic lupus erythematosus

Area of Science:

• Cardiology
• Rheumatology
• Immunology

Background:

• Systemic lupus erythematosus (SLE) is associated with significantly increased cardiovascular disease (CVD) morbidity and mortality.
• Both major adverse cardiovascular events and subclinical atherosclerosis are prevalent in SLE patients.
• Traditional cardiac risk factors alone do not fully explain the elevated CVD risk in SLE.

Purpose of the Study:

• To explore the multifaceted risk factors contributing to cardiovascular disease in patients with systemic lupus erythematosus.
• To highlight the role of SLE-specific factors in the pathogenesis of atherosclerosis.
• To discuss current strategies and ongoing research for CVD risk prediction and prevention in SLE.

Main Methods:

• Review of existing literature on cardiovascular risk in SLE.
• Analysis of the contribution of traditional, lupus-related, medication, and genetic factors.
• Examination of the role of SLE-specific inflammation in atherogenesis.

Main Results:

• Cardiovascular risk in SLE is influenced by traditional factors, disease-specific inflammation (cytokines, oxidized lipids, immune cells), medications, and genetics.
• SLE-specific inflammation is implicated in the development of atherosclerotic plaques.
• Biomarkers for CVD risk prediction in SLE are under investigation.

Conclusions:

• Cardiovascular disease is a major concern in SLE, driven by a complex interplay of factors.
• Minimizing traditional cardiac risk factors and controlling lupus disease activity are current primary management strategies.
• Further research is needed to identify specific biomarkers and develop targeted SLE-based CVD prevention strategies.